BrandShield (LSE: BRSD), together with the Pharmaceutical Security Institute, announced its annual Pharma Fraud report following a disruption program carried out from January 2022 to January 2023 involving the monitoring, detecting, and removal of online threats. The new report highlights the extent of global criminal fraud targeting both innocent patients and pharmaceutical companies. The removed listings contained a variety of medicines relating to various cancers, HIV, and type 2 di.